Table 1.
Characteristics of currently licensed, live, oral rotavirus vaccines
| Product | Manufacturer | WHO PQ? | Doses | Composition | Formulation/storage | Presentation |
| Globally licensed | ||||||
| Rotarix | GSK | Y | 3 | G1P[8] | Liquid 2–8 °C for 36 months | One-dose plastic tube | Strip of 5-single-dose plastic tubes |
| RotaTeq | Merck | Y | 2 | G1, G2, G3, G4, P[8] | Liquid 2–8 °C for 24 months | One-dose plastic tube |
| Rotavac | Bharat Biologicals | Y | 3 | G9P[11] | Liquid frozen −20 °C long-term | 2–8 °C for 7 monthsa | 5-dose or 10-dose glass vial, with dose dropper |
| ROTASIIL | Serum Institute of India | Y | 3 | G1, G2, G3, G4, G9 | Lyophilized < 25 °C for 30 months | <40 °C for 18 monthsb | One-dose or two-dose glass vial, with vial of diluent, adapter, and syringe |
| Nationally licensed | ||||||
| Rotavin-M1 | POLYVAC | N | 3 | G1P[8] | Liquid frozen -20 °C for 24 months | 2–8 °C for 2 months | One-dose vial |
| Lanzhou Lamb Rotavirus Vaccine | Lanzhou Institute of Biological Products | N | 1 annually age 2 months to 3 years | G10P[15] | Liquid | Vial |
aNonfrozen presentation expected in 2020 but not yet prequalified.
bLiquid presentation expected in 2020 but not yet prequalified.